Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134394 · ClinicalTrials.gov registry record · Phase 2
Etanercept With Tacrolimus for Psoriasis
A Phase 2 study of Psoriasis, sponsored by University of Medicine and Dentistry of New Jersey.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00134394: Completed Phase 2 study of Psoriasis, sponsored by University of Medicine and Dentistry of New Jersey.
NCT00134394 is a Phase 2 study of Psoriasis that has completed, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 20 participants, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00134394, a Phase 2 study of Psoriasis, has completed, sponsored by University of Medicine and Dentistry of New Jersey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is designed to evaluate the efficacy of etanercept 50 mg subcutaneously (SQ) weekly plus tacrolimus 0.1% topical ointment twice daily compared to etanercept 50 mg SQ weekly plus placebo ointment twice daily.
Conditions Studied
Interventions
- DRUG Etanercept plus tacrolimus
Study Locations (1)
New Jersey
- UMDNJ Psoriasis Center of Excellence - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-02 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
What the finished NCT00134394 record still lists
NCT00134394 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Etanercept plus tacrolimus is the first listed.
NCT00134394 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00134394 about?
NCT00134394 is a clinical study titled "Etanercept With Tacrolimus for Psoriasis". The study is designed to evaluate the efficacy of etanercept 50 mg subcutaneously (SQ) weekly plus tacrolimus 0.1% topical ointment twice daily compared to etanercept 50 mg SQ weekly plus placebo ointment twice daily.
What is the current status of trial NCT00134394?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2005-02. Estimated completion is 2007-12.
What conditions does trial NCT00134394 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT00134394?
The interventions under investigation include: Etanercept plus tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00134394?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00134394 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00134394's enrollment target sits among peer trials
20 107th of 125 higher than 16 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
-
Randomized Study of PH-10 for Psoriasis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia